Lemin Zheng has a total of 935 co-authors. Here are the top co-authors by number of shared publications:

  • Mingming Zhao

    Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University; Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China

    36 shared publications
  • Bing Pan

    The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Key Laboratory of Molecular Cardiovascular Sciences of Education Ministry, and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides of Health Ministry, Beijing, People’s Republic of China

    26 shared publications
  • Liang Ji

    The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing 100191, China

    24 shared publications
  • Qi Zhang

    The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, China

    18 shared publications
  • Rui Zhan

    NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functional Recovery; Research Center for Cardiopulmonary Rehabilitation, University of Health and Rehabilitation Sciences Qingdao Hospital (Qingdao Municipal Hospital); School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China

    18 shared publications
  • Jing Xue

    Beijing Tiantan Hospital, National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China

    16 shared publications

Latest Publications

  • SYVN1-mediated succinate accumulation exacerbates heart failure

    by Hongtu Cui, Lu Fang, Huanhuan Cao, Rui Zhan, Yawen Deng, Mingming Zhao, Xin Guo, Haiyi Yu, Wenli Xu, Yanbo Xue, et al.

  • Open Access

    Metabolomic Profiles and Changes During the 20 Years Preceding Heart Failure

    by Jiangtao Li, Shusi Ding, Zhao Yang, Mingdan Wang, Xuan Deng, Xueting Sun, Wenting Lu, Pingping Jia, Yan Liu, Yuhan Zhang, et al.

    BACKGROUND: Longitudinal metabolomic studies can refine understanding of heart failure (HF) progression and enable precision prevention. This study aims to identify serum metabolites associated with HF risk via longitudinal metabolomic analysis, delineate their dynamic trajectories, and explore metabolite profiles in populations with different metabolic disorders. METHODS: This study analyzed longitudinal serum metabolomic data from 4774 serum samples from 1728 HF-free participants in the Chinese Multi-Provincial Cohort Study Metabolomics Project at 4 time points over a 20-year follow-up. Intensity models and Cox proportional-hazards models identified metabolites associated with HF risk. Latent variable mixed-effects models evaluated metabolite trajectories. RESULTS: Of the 784 detected metabolites, 23 were associated with HF risk at a false discovery rate–adjusted P 5 years before clinical HF diagnosis, with most changes initiating 15 to 20 years before clinical manifestation. Populations with different metabolic disorders exhibited distinct metabolite profiles related to HF. The HF-associated metabolites were primarily involved in energy metabolism and the vasodilatory response among individuals with hypertension, lipotoxic effects and oxidative stress among those with obesity, and inflammatory processes and glucotoxic mechanisms among individuals with dysglycemia. CONCLUSIONS: This longitudinal metabolomic study identifies HF-associated metabolite profiles, characterizes their changes during the 20 years preceding clinical diagnosis, and reveals heterogeneity across individuals with different metabolic disorders, thereby informing future biomarker and intervention research.

  • Open Access

    Multi‐omics–driven precision medicine

    by Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, et al.

    Precision medicine is increasingly constrained not by a lack of molecular data but by the absence of frameworks that can translate multidimensional biological information into actionable clinical decisions. Multi‐omics‐driven precision medicine (MODPM) addresses this lack by integrating genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome, and clinical context into a multiscale framework that links molecular mechanisms, tissue organization, and patient trajectories. In this review, we propose a conceptual framework for MODPM and examine how advances in multi‐omics technologies, artificial intelligence (AI), and foundation models are reshaping disease modeling, drug development, and precision intervention. We summarize the biological contributions of major omics layers and discuss how AI supports cross‐modal representation learning, contextual modeling, and perturbation‐aware prediction. We highlight drug development as a key translational application of MODPM and further discuss its clinical relevance across three major disease contexts: cancer, autoimmune diseases, and metabolic disorders, including cardiometabolic and renal–metabolic diseases. These examples illustrate how MODPM can support target discovery, disease endotyping, treatment response prediction, and clinical monitoring by analyzing shared mechanisms such as immune dysregulation, metabolic remodeling, chronic inflammation, tissue microenvironmental changes, and gene–environment interactions. Across these settings, MODPM enables finer molecular stratification, the identification of pathway‐dominant disease states, improved response prediction, and dynamic treatment monitoring. We also discuss key barriers to implementation, including data heterogeneity, limited cohort diversity, polygenic complexity, workflow constraints, cost, and ethical issues related to privacy, consent, and data ownership. Overall, the value of MODPM lies not in stacking additional data layers but in building a multiscale, continuously learnable framework to link biological heterogeneity to clinically interpretable and actionable decisions.


  • Open Access

    Therapeutic Translation of Epicardial Adipose Tissue Targeting in Heart Failure With Preserved Ejection Fraction: How Far Are We?

    by Wensheng Qi, Yue Li, Chenggong Jiang, Ruiyu Wang, Xi Jiang, Lei Pang, Sheng Wang, Lemin Zheng, Chi‐Ming Wong, Yin Cai

    Heart failure with preserved ejection fraction (HFpEF) exhibits an inflammatory‐metabolic phenotype in association with multiple factors. Among them, epicardial adipose tissue (EAT), a type of visceral adipose tissue surrounding the heart, has been gaining attention. EAT expansion is associated with the development of HFpEF, the increased risk for heart failure–related mortality in patients with HFpEF, independent of age, body mass index, diabetes, and sex. Thus, reducing EAT expansion has been proposed as a promising therapeutic strategy for treating HFpEF. Although specific treatment for EAT expansion is unavailable, modulating the inflammatory response and systemic energy metabolism are beneficial in improving clinical symptoms or prognosis in patients with HFpEF. To further enhance our capacity in effectively treating HFpEF, this review discusses the knowledge gaps between EAT expansion and the lack of a platform to reduce EAT expansion in HFpEF, including the choices of appropriate animal models, the conceptual mechanisms of glucose and lipid metabolism in EAT expansion toward potential strategies for selective EAT‐targeted therapeutic avenues.

  • Metabolomics and Cardiovascular Disease

    by Lemin Zheng, Xiaoyi Liu, Haibin Wang, Hao Li, Xiaoyu Liu, Chengyu Hao

  • Open Access

    A plasma N-acetyl amino acid panel for type 2 diabetes discrimination built by targeted LC–MS/MS: A case–control study

    by Shusi Ding, Zhanxiong Xie, Daqiu Chen, Xiaomai Huang, Qiutong Wu, Lemin Zheng, Shanghua Xu, Shunxiang Luo

    Background: Type 2 diabetes (T2D) is characterized by profound metabolic disturbances, yet clinically actionable biomarkers beyond conventional glycaemic indices remain limited. N-acetyl amino acids (NAcAAs) are emerging metabolites linked to amino acid metabolism and acetylation status, but their quantitative profile and diagnostic relevance in T2D have not been systematically defined. Objectives: To characterize the plasma NAcAA profile in T2D using a targeted LC–MS/MS approach, to evaluate associations between individual NAcAAs and clinical traits, and to develop a metabolite-based panel for T2D discrimination. Methods: In this case–control study, we developed and validated a targeted LC–MS/MS assay for the absolute quantification of 19 plasma NAcAAs. The assay was applied to 174 individuals with T2D and 68 non-diabetic controls. Global metabolic differences were assessed by principal component analysis and hierarchical clustering. Associations between NAcAAs and clinical traits were examined by correlation analysis and multivariable logistic regression. Least absolute shrinkage and selection operator (LASSO) logistic regression was used to construct a compact diagnostic signature. Model performance was evaluated by receiver operating characteristic (ROC) analysis, calibration, and decision curve analysis. Results: The plasma NAcAA landscape differed substantially between T2D and controls, with coordinated increases in metabolites such as N-acetyltryptophan and decreases in several others, including N-acetylproline, N-acetylglutamine, and N-acetyllysine. Differential NAcAAs were significantly associated with glycaemic traits, particularly fasting glucose and HbA1c, as well as renal-related markers including urea nitrogen and creatinine. In adjusted logistic regression models, N-acetyltryptophan was positively associated with T2D (OR = 9.452, 95% CI 4.421–20.211). In contrast, several NAcAAs showed inverse associations, including N-acetylproline (OR = 0.041, 95% CI 0.015–0.111) and N-acetyllysine (OR = 0.088, 95% CI 0.038–0.203). An 8-metabolite panel derived by LASSO achieved excellent discriminatory performance (AUC = 0.963, 95% CI 0.942–0.984), with good calibration and favorable net clinical benefit. Conclusion: Targeted quantitative profiling of plasma NAcAAs identifies a distinct metabolic signature associated with T2D. A compact NAcAA-based panel shows strong potential for T2D discrimination and may serve as a complementary tool for metabolic risk characterization and translational biomarker development.

  • Open Access

    Metabolic dysfunction-associated steatohepatitis exacerbated by Clostridium perfringens-derived ammonia is attenuated by tripeptide DT-109

    by Pengxiang Qu, Shusi Ding, Yanru Zhang, Yang Zhao, Erfei Song, Liangshuo Hu, Ruike Ding, Wenbin Cao, Yiting Hou, Jia Qi, et al.

    The global prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is rising, driven by a complex interplay of metabolic disturbances, inflammation, and fibrosis, yet effective treatment options remain limited. This study examined the relationships among intestinal microbial dysbiosis, ammonia production, and hepatic CD8+ T cell activity in MASH, and assessed the therapeutic potential of DT-109, a glycine-based tripeptide. We investigated the gut-liver axis across human cohorts and both non-human primate and mouse MASH models. Multi-omics approaches were used to characterize ileal microbiota, ammonia levels, and hepatic immune and metabolic pathways. Causality was verified through microbiota transplantation, C. perfringens NirA-knockout mutants, and functional validation in vitro and in vivo. The efficacy of DT-109 was evaluated in non-human primates and mice. Our results revealed a significant increase in the ammonia-producing gut bacterium C. perfringens, which led to elevated intestinal ammonia and disruption of the intestinal barrier in MASH. Elevated ammonia levels triggered FosB-mediated upregulation of chemokine C-C motif ligand 5 (CCL5) in CD8+ T cells, which in turn drove T cell cytotoxicity in the liver. Notably, DT-109 effectively lowered C. perfringens abundance, reduced intestinal ammonia, restored intestinal barrier integrity, and alleviated CD8+ T cell dysregulation in MASH. These results identify a distinct mechanism in which gut-derived ammonia drives CD8+ T cell-mediated MASH and demonstrate that DT-109 effectively targets this axis by inhibiting C. perfringens and reducing ammonia, ultimately ameliorating MASH.


  • Open Access

    Microvascular endothelial scavenger receptor class B type I protects against heart failure with preserved ejection fraction by inhibiting T-cell cardiotropism

    by Yufei Wu, Xiaomei Yang, Yu Bai, Chenze Li, Peng Wang, Qing Xu, Hui Li, Xiaoli Rao, Yangkai Xu, Jie Chen, et al.

    Cardiac microvascular endothelial cells (CMECs) dysfunction is a well-recognized mediator of heart failure with preserved ejection fraction (HFpEF), but the underlying mechanism remains unclear. Here we find that scavenger receptor class B type I (SR-B1) is predominantly expressed in CMECs and decreased significantly in HFpEF. Endothelial-specific SR-B1 deficiency exacerbates cardiac pathological remodeling and diastolic dysfunction in HFpEF, which can be prevented by endothelial SR-B1 reconstitution through adeno-associated virus serotype 1 (AAV1)-mediated delivery in endothelial-specific SR-B1-deficient mice. Single-cardiac-endothelial-cell transcriptomics and lineage-tracing system reveal that inflammatory CMECs subcluster activation is responsible for the deteriorating HFpEF progression induced by endothelial SR-B1 loss, rather than endothelial-to-mesenchymal transition. Mechanistically, SR-B1 loss drives increased CXCL10 secretion, which orchestrates CMECs activation and CXCR3-positive T-cell cardiotropism to promote diastolic dysfunction—a process associated with endothelial IRF1 activation. Most importantly, the SR-B1-CXCL10-CXCR3 axis is activated in human HFpEF cardiac tissue, and the elevated CXCL10 level in plasma is independently associated with a higher HFpEF prevalence. This study uncovers that activation of the SR-B1–CXCL10-CXCR3 axis in CMECs aggravates HFpEF pathogenesis through the accumulation of CXCR3-positive T-cells in hearts.


  • Open Access

    Correction: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma

    by Jian Kong, Fandong Kong, Jun Gao, Qiangbo Zhang, Shuying Dong, Fang Gu, Shan Ke, Bing Pan, Qiang Shen, Huichuan Sun, et al.